Cannabis Science Pioneer Tikun Olam Expands Partnership with MariMed to Bring Branded Cannabis Products to More U.S. MMJ States

This new agreement brings Tikun Olam's premium cannabis products, years of proprietary, peer-reviewed scientific research and unprecedented clinical data collection to four additional MMJ-legal U.S. states, its most expansive agreement to date. Tikun Olam and MariMed's relationship began in 2015 with a pilot program in Delaware and marked the first time that U.S. patients had access to the world's only cannabis strains proven to deliver symptomatic relief for specific conditions including cancer, PTSD, epilepsy, Crohn's Disease/Colitis, chronic pain and neuropathy to name a few.

"After the great success of our program in Delaware, MariMed is excited to bring Tikun™ to our expanding national network of legal cannabis production and dispensary facilities," says Robert Fireman, CEO of MariMed Inc. "Tikun Olam's empirical data on clinical effectiveness is unsurpassed, and we look forward to educating healthcare professionals and offering Tikun's products to tens of thousands of new patients nationwide."

MariMed will introduce Tikun's exclusive strains and products in state-of-the-art, regulatory compliant and fully operational cultivation and medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun products will be available in flower, vape cartridges, topicals, tinctures and edibles utilizing at least six Tikun™ branded strains, including its world-renowned Avidekel™ high-CBD strain.  In addition to Delaware, Tikun™ products have launched in Nevada (March 2017) and are expected to launch Washington (November 2017).

"Tikun Olam is delighted to expand our relationship with MariMed," says Tikun CEO Bernard Sucher.  "MariMed utilizes the "best practices" and standards for cultivation and production and their qualified distribution channels allow us to bring our proven wellness products to more U.S. patients than ever before."

About Tikun Olam
Tikun Olam ("repair the world" in Hebrew) is the world's leading cannabis brand and globally recognized as the pioneer of modern medical cannabis. Operating as a commercial venture for over 10 years, Tikun Olam's products have been used since 2010 in ongoing clinical trials in Israel's regulated medical cannabis market, treating over 10,000 patients for a variety of symptoms of medical conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn's Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy. Through this access to patients, medical personnel and data collection, Tikun Olam has developed multiple proprietary strains, including the first-ever, high-CBD, "high-less" strain Avidekel™, its popular high-THC strain Alaska™, and its "one-to-one" CBD/THC strain Midnight™. Tikun Olam's U.S. operations, established in 2015 as T.O. Global LLC, is a joint venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar partnerships in Canada (TSX: LEAF), Australia, Germany and South Africa, all in support of its global mission to educate the traditional medical community and its patients on the applications of cannabis as a scientifically proven wellness product. Visit www.tikunolamusa.com, and follow us on Facebook, Twitter, and Instagram.

About MariMed
MariMed is an industry leading professional management company in the emerging cannabis industry. Marimed designs, develops, operates, funds, and optimizes medical cannabis cultivation, production, and dispensary facilities. MariMed's team has developed state-of-the-art, regulatory-compliant legal cannabis facilities in multiple states. These facilities are models of excellence in horticultural principles, cannabis production, product development, and dispensary operations. MariMed is on the forefront of precision-dosed cannabis medicine for the treatment of specific medical conditions. MariMed's branded products, such as Kalm Fusion™, are being licensed and distributed in legal cannabis states across the country. For additional information, visit www.MarimedAdvisors.com.

Forward-Looking Statements
This release contains certain forward-looking statements and information relating to MariMed Inc. (the "Company") that are based on the current beliefs of the Company's management, as well as assumptions made by, and information currently available to, the Company. Such statements reflect the current views of the Company with respect to future events and are subject to certain assumptions, including those described in this release. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "should," "could," "anticipate," "believe," "intend," "plan," "might," "potentially" or "expect." The Company does not intend to update these forward-looking statements.

SOURCE Tikun Olam

Related Links

http://www.tikunolamusa.com